A nomogram for predicting lowâ€volume/lowâ€grade p

Cancer

110, 2441-2447

DOI: 10.1002/cncr.23055

Citation Report

#	Article	IF	Citations
2	Prostate cancer. Critical Reviews in Oncology/Hematology, 2008, 68, S32-S36.	2.0	16
3	Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer, 2008, 113, 701-709.	2.0	86
4	Preliminary Results of a Novel Method to Estimate the Probability of Prostate Cancer in Men with Elevated Serum PSA Values. European Urology, 2008, 54, 701-702.	0.9	1
5	Avoiding surgery in prostate cancer patients with low-risk disease. Therapy: Open Access in Clinical Medicine, 2008, 5, 25-36.	0.2	3
6	Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nature Reviews Urology, 2008, 5, 362-363.	1.4	4
7	Tumor Amount in Prostatic Tissues in Relation to Patient Outcome and Management. American Journal of Clinical Pathology, 2009, 131, 7-10.	0.4	12
8	Usefulness of Cytokeratin 5/6 and AMACR Applied as Double Sequential Immunostains for Diagnostic Assessment of Problematic Prostate Specimens. American Journal of Clinical Pathology, 2009, 132, 211-220.	0.4	27
9	Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy. European Urology, 2009, 55, 617-628.	0.9	25
10	Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. European Urology, 2009, 55, 1321-1332.	0.9	155
11	The Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance. European Urology, 2009, 56, 891-898.	0.9	58
12	Predictive models in diagnosing indolent cancer. Cancer, 2009, 115, 3100-3106.	2.0	21
13	The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice. Histopathology, 2009, 55, 384-391.	1.6	60
14	External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU International, 2009, 104, 1661-1667.	1.3	19
15	Radical prostatectomy findings in patients predicted to have lowâ€volume/lowâ€grade prostate cancer diagnosed by extendedâ€core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU International, 2010, 105, 1386-1391.	1.3	25
16	Prebiopsy PSA Velocity Not Reliable Predictor of Prostate Cancer Diagnosis, Gleason Score, Tumor Location, or Cancer Volume After TTMB. Urology, 2009, 74, 171-176.	0.5	16
17	Prostate Cancer With Tertiary Gleason Pattern 5 in Prostate Needle Biopsy. American Journal of Surgical Pathology, 2009, 33, 233-240.	2.1	39
18	Testing the most stringent criteria for selection of candidates for active surveillance in patients with lowâ€risk prostate cancer. BJU International, 2010, 105, 1548-1552.	1.3	49
19	â€˜Insignificantâ€™ prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme â€˜lowâ€volume/ lowâ€gradeâ€™ prostate cancer?. BJU International, 2010, 106, 304-315.	1.3	18

#	Article	IF	Citations
20	Lowering the PSA Threshold for Prostate Biopsy from 4 to 2.5 ng/ml: Influence on Cancer Characteristics and Number of Men Needed to Biopt. Urologia Internationalis, 2010, 84, 141-146.	0.6	4
21	Pathological Findings and Prostate Specific Antigen Outcomes After Radical Prostatectomy in Men Eligible for Active Surveillanceâ€"Does the Risk of Misclassification Vary According to Biopsy Criteria?. Journal of Urology, 2010, 183, 539-545.	0.2	78
22	Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen. Journal of Urology, 2010, 183, 520-528.	0.2	344
23	A New Preoperative Nomogram to Predict Minimal Prostate Cancer: Accuracy and Error Rates Compared to Other Tools to Select Patients for Active Surveillance. Journal of Urology, 2011, 186, 1811-1817.	0.2	20
24	Nomogram to Predict Insignificant Prostate Cancer at Radical Prostatectomy in Korean Men: A Multi-Center Study. Yonsei Medical Journal, 2011, 52, 74.	0.9	8
25	Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. BJU International, 2011, 108, 513-517.	1.3	39
26	Prediction of pathological outcomes for a single microfocal (â‰¤3â€ƒmm) Gleason 6 prostate cancer detected via contemporary multicore (â‰¥12) biopsy in men with prostateâ€specific antigen â‰¤10â€ƒng/mL. BJU International, 2011, 108, 1101-1105.	1.3	4
27	The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. European Urology, 2011, 60, 291-303.	0.9	267
28	Active Surveillance for Prostate Cancer: Progress and Promise. Journal of Clinical Oncology, 2011, 29, 3669-3676.	0.8	264
29	Active Surveillance for Prostate Cancer: An Underutilized Opportunity for Reducing Harm. Journal of the National Cancer Institute Monographs, 2012, 2012, 175-183.	0.9	19
30	International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. British Journal of Cancer, 2012, 107, 1467-1473.	2.9	23
31	Defining and predicting indolent and low risk prostate cancer. Critical Reviews in Oncology/Hematology, 2012, 83, 235-241.	2.0	20
32	The accuracy of pathological data for the prediction of insignificant prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 760-768.	0.7	3
33	The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance. European Urology, 2012, 61, 356-362.	0.9	28
34	The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU International, 2012, 109, 1170-1176.	1.3	67
35	Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer. BJU International, 2012, 110, E564-9.	1.3	9
36	Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. European Urology, 2013, 64, 693-699.	0.9	78
37	Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1060-1066.	0.8	16

#	Article	IF	Citations
38	Comparative Validation of Nomograms Predicting Clinically Insignificant Prostate Cancer. Urology, 2013, 81, 1202-1208.	0.5	17
39	Localization of higher grade tumor foci in potential candidates for active surveillance who opt for radical prostatectomy. Prostate International, 2013, 1, 152-157.	1.2	2
40	Focal Therapy and the Index Lesion Hypothesis in Prostate Cancer. Medical Radiology, 2013, , 173-183.	0.0	0
41	Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU International, 2014, 114, E18-E24.	1.3	43
42	Implementation of PSA-based active surveillance in prostate cancer. Biomarkers in Medicine, 2014, 8, 747-753.	0.6	4
43	Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. International Scholarly Research Notices, 2014, 2014, 1-16.	0.9	0
44	The Percentage of Core Involved by Cancer Is the Best Predictor of Insignificant Prostate Cancer, According to an Updated Definition (Tumor Volume up to 2.5 cm3): Analysis of a Cohort of 210 Consecutive Patients With Low-risk Disease. Urology, 2014, 83, 28-32.	0.5	18
45	Prostate Cancer Nomograms: A Review of Their Use in Cancer Detection and Treatment. Current Urology Reports, 2014, 15, 391.	1.0	22
46	Insignificant disease among men with intermediate-risk prostate cancer. World Journal of Urology, 2014, 32, 1417-1421.	1.2	13
47	Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance. Journal of Urology, 2015, 193, 1943-1949.	0.2	60
48	Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 137-143.	2.0	11
49	Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?. Clinical Genitourinary Cancer, 2015, 13, 499-504.	0.9	5
50	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	1.3	27
51	Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer. European Urology, 2016, 69, 223-228.	0.9	22
52	Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?. Journal of Urology, 2016, 195, 74-79.	0.2	27
53	Six-core versus twelve-core prostate biopsy: a retrospective study comparing accuracy, oncological outcomes and safety. Irish Journal of Medical Science, 2016, 185, 219-223.	0.8	4
54	Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy. Scandinavian Journal of Urology, 2017, 51, 27-32.	0.6	14
56	Combination of prostate imaging reporting and data system (<scp>PI</scp>â€<scp>RADS</scp>) score and prostateâ€specific antigen (<scp>PSA</scp>) density predicts biopsy outcome in prostate biopsy naÃ¯ve patients. BJU International, 2017, 119, 225-233.	1.3	244

#	Article	IF	Citations
57	Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. European Urology, 2017, 72, 135-141.	0.9	20
59	The Role of Transrectal Ultrasound for Finding Focal Lesions in Prostate Cancer Detection Compared to Systematic Sextant Biopsy. Academic Radiology, 2019, 26, 1023-1029.	1.3	0
60	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. World Journal of Urology, 2020, 38, 663-671.	1.2	10
61	Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. Urology, 2020, 137, 126-132.	0.5	7
62	Decision Support for Low-Risk Prostate Cancer. , 2016, , 207-213.		1
63	Expending the Paradigm: Active Surveillance for Intermediate Risk Prostate Cancer. Open Journal of Urology, 2018, 08, 248-256.	0.0	0